US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma Β· Body weight management Β· Acromegaly
Camurus Pty Ltd
Currus Biologics Pty drug portfolio β 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 14 drugs and development assets β regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Currus Biologics Pty drug portfolio β 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Mechanism: Unknown.
Development asset linked to Currus Biologics Pty in public FDA and regional records.
Development asset linked to Currus Biologics Pty in public FDA and regional records.
Development asset linked to Currus Biologics Pty in public FDA and regional records. Mechanism: Somatostatin receptor 2 agonist.
Development asset linked to Currus Biologics Pty in public FDA and regional records.
Systemic hormonal preparations (H01) compound in Currus Biologics Pty's portfolio. Mechanism: Somatostatin receptor agonist.
US regulatory status: approved. Molecular target: Somatostatin receptor.
Development asset linked to Currus Biologics Pty in public FDA and regional records.
US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
Development asset linked to Currus Biologics Pty in public FDA and regional records.
Development asset linked to Currus Biologics Pty in public FDA and regional records.
Development asset linked to Currus Biologics Pty in public FDA and regional records.
Development asset linked to Currus Biologics Pty in public FDA and regional records.
Development asset linked to Currus Biologics Pty in public FDA and regional records.